-
Mashup Score: 2
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL @ASH_hematology #ASH24 #lymsm #oncology https://t.co/QT7TkcOux5
-
-
Mashup Score: 1
Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL @ASH_hematology #ASH24 #lymsm #oncology https://t.co/QT7TkcOux5
-
-
Mashup Score: 3
Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma @LymphClinician @ASH_hematology #ASH24 #lymsm #oncology https://t.co/KFp2xGh6B0
-
-
Mashup Score: 4
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL @MDAndersonNews @ASH_hematology #ASH24 #lymsm #oncology https://t.co/A5Mx4AJAqF
-
-
Mashup Score: 2
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL @ASH_hematology #ASH24 #lymsm #oncology https://t.co/THah9KGYBP
-
-
Mashup Score: 1Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL - 12 day(s) ago
Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL @ASH_hematology #ASH24 #lymsm #oncology https://t.co/C6m93TVWJA
-
-
Mashup Score: 2
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma @ASH_hematology #ASH24 #lymsm #oncology https://t.co/1KJUEymWPV
-
-
Mashup Score: 3
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL @ASH_hematology #ASH24 #lymsm #oncology https://t.co/WOVGQZ36ZM
-
-
Mashup Score: 1
Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL @ASH_hematology #ASH24 #lymsm #oncology https://t.co/QT7TkcOux5
-
Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma @ASH_hematology #ASH24 #lymsm #oncology https://t.co/1KJUEymWPV